Open access
Jul 2026
Longitudinal plasma proteomics separates diagnostic differences from progression-linked changes in Alzheimer’s disease
By distinguishing diagnostic-state markers from progression-linked changes, this longitudinal, multi-domain approach prioritizes proteins for validation as markers of AD progression and for mechanistic and therapeutic follow-up.
Junyoung Park, Y. le Guen, A. Peña-Tauber et al.
· medRxiv · 0 citations